Clearside Biomedical (CLSD) Stock Forecast & Price Target

Compare

1,021 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CLSD Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Clearside

Biomedical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CLSD Stock 12 Month Forecast

Average Price Target

$5.40

▲(558.54%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Clearside Biomedical in the last 3 months. The average price target is $5.40 with a high forecast of $8.00 and a low forecast of $3.00. The average price target represents a 558.54% change from the last price of $0.82.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.74,1.2984615384615386,1.856923076923077,2.4153846153846157,2.9738461538461536,3.5323076923076924,4.090769230769231,4.649230769230769,5.207692307692308,5.766153846153847,6.3246153846153845,6.883076923076923,7.441538461538462,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.74,1.0984615384615384,1.456923076923077,1.8153846153846154,2.1738461538461538,2.5323076923076924,2.890769230769231,3.2492307692307696,3.607692307692308,3.966153846153847,4.324615384615385,4.683076923076923,5.041538461538462,{"y":5.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.74,0.9138461538461538,1.0876923076923077,1.2615384615384615,1.4353846153846153,1.609230769230769,1.783076923076923,1.9569230769230768,2.1307692307692303,2.304615384615384,2.478461538461538,2.652307692307692,2.8261538461538462,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.58,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$8.00

Average Price Target$5.40

Lowest Price Target$3.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

21.95%

Upside

Reiterated

07/08/25

The most significant factor impacting Clearside Biomedical's score is the company's poor financial performance, characterized by declining revenues and negative cash flows. Technical indicators suggest the stock lacks momentum, with valuation metrics further highlighting challenges due to persistent losses.

Yi ChenH.C. Wainwright

H.C. Wainwright

$6→$5

Buy

509.76%

Upside

Reiterated

05/27/25

Clearside Biomedical (CLSD) Gets a Buy from H.C. Wainwright

Jonathan WollebenCitizens JMP

Citizens JMP

Buy

509.76%

Upside

Reiterated

05/16/25

Citizens JMP Keeps Their Buy Rating on Clearside Biomedical (CLSD)

Debanjana ChatterjeeJonesTrading

JonesTrading

Buy

631.71%

Upside

Reiterated

05/15/25

Clearside Biomedical: Undervalued Opportunity with Strategic Partnerships and Promising CLS-AX Advancements

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

Buy

875.61%

Upside

Reiterated

05/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vor Biopharma (NASDAQ: VOR), Clearside Biomedical (NASDAQ: CLSD) and Argenx Se (NASDAQ: ARGX)

Serge BelangerNeedham

Needham

$4→$3

Buy

265.85%

Upside

Reiterated

05/15/25

Needham Remains a Buy on Clearside Biomedical (CLSD)

Andreas ArgyridesOppenheimer

Oppenheimer

Buy

509.76%

Upside

Reiterated

11/13/24

Oppenheimer Keeps Their Buy Rating on Clearside Biomedical (CLSD)

Daniil GataulinChardan Capital

Chardan Capital

Buy

631.71%

Upside

Initiated

08/21/24

Clearside Biomedical initiated with a Buy at ChardanClearside Biomedical initiated with a Buy at Chardan

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

21.95%

Upside

Reiterated

07/08/25

Yi ChenH.C. Wainwright

H.C. Wainwright

$6→$5

Buy

509.76%

Upside

Reiterated

05/27/25

Clearside Biomedical (CLSD) Gets a Buy from H.C. Wainwright

Jonathan WollebenCitizens JMP

Citizens JMP

Buy

509.76%

Upside

Reiterated

05/16/25

Citizens JMP Keeps Their Buy Rating on Clearside Biomedical (CLSD)

Debanjana ChatterjeeJonesTrading

JonesTrading

Buy

631.71%

Upside

Reiterated

05/15/25

Clearside Biomedical: Undervalued Opportunity with Strategic Partnerships and Promising CLS-AX Advancements

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

Buy

875.61%

Upside

Reiterated

05/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vor Biopharma (NASDAQ: VOR), Clearside Biomedical (NASDAQ: CLSD) and Argenx Se (NASDAQ: ARGX)

Serge BelangerNeedham

Needham

$4→$3

Buy

265.85%

Upside

Reiterated

05/15/25

Needham Remains a Buy on Clearside Biomedical (CLSD)

Andreas ArgyridesOppenheimer

Oppenheimer

Buy

509.76%

Upside

Reiterated

11/13/24

Oppenheimer Keeps Their Buy Rating on Clearside Biomedical (CLSD)

Daniil GataulinChardan Capital

Chardan Capital

Buy

631.71%

Upside

Initiated

08/21/24

Clearside Biomedical initiated with a Buy at ChardanClearside Biomedical initiated with a Buy at Chardan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Clearside Biomedical

1 Month

xxx

Success Rate

14/34 ratings generated profit

Average Return

+3.88%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 41.18% of your transactions generating a profit, with an average return of +3.88% per trade.

3 Months

xxx

Success Rate

11/34 ratings generated profit

Average Return

-0.63%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 32.35% of your transactions generating a profit, with an average return of -0.63% per trade.

1 Year

Yi ChenH.C. Wainwright

Success Rate

7/16 ratings generated profit

Average Return

-2.69%

reiterated a buy rating last month

Copying Yi Chen's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of -2.69% per trade.

2 Years

xxx

Success Rate

4/34 ratings generated profit

Average Return

-32.23%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 11.76% of your transactions generating a profit, with an average return of -32.23% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CLSD Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CLSD has received 8 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. CLSD average Analyst price target in the past 3 months is 5.40.

Each month's total comprises the sum of three months' worth of ratings.

CLSD Financial Forecast

CLSD Earnings Forecast

Next quarter’s earnings estimate for CLSD is -$0.10 with a range of -$0.12 to -$0.08. The previous quarter’s EPS was -$0.11. CLSD beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.99% of the time in the same period. In the last calendar year CLSD has Preformed in-line its overall industry.

CLSD Sales Forecast

Next quarter’s sales forecast for CLSD is $498.00K with a range of $0.00 to $2.30M. The previous quarter’s sales results were $2.33M. CLSD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.79% of the time in the same period. In the last calendar year CLSD has Preformed in-line its overall industry.

CLSD Stock Forecast FAQ

What is CLSD’s average 12-month price target, according to analysts?

Based on analyst ratings, Clearside Biomedical’s 12-month average price target is 5.40.

What is CLSD’s upside potential, based on the analysts’ average price target?

Clearside Biomedical has 558.54% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CLSD a Buy, Sell or Hold?

Clearside Biomedical has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Clearside Biomedical’s price target?

The average price target for Clearside Biomedical is 5.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $3.00. The average price target represents 558.54% Increase from the current price of $0.82.

What do analysts say about Clearside Biomedical?

Clearside Biomedical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of CLSD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Clearside Biomedical (CLSD) Stock Forecast & Price Target

CLSD Analyst Ratings

CLSD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Clearside Biomedical

CLSD Analyst Recommendation Trends

CLSD Financial Forecast

CLSD Earnings Forecast

CLSD Sales Forecast

CLSD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts